Daniel A. Laheru - Concepedia

Author

Daniel A. Laheru

Also Known As

D A Laheru, D LAHERU, D Laheru, D. A Laheru, D. A. Laheru, D. Laheru, D.A. Laheru, Daniel A Laheru, Daniel A. Laheru, Daniel Laheru

635

Publications

35.8K

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine Cancer Research Center Sidney Kimmel Cancer Center

About

Daniel A. Laheru is an author at Johns Hopkins University specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	75	12K
2	Health Sciences	17	20	6.2K
3	Natural Sciences	1	1	20
4	Public Health	1	1	13
5	Allergy	1	1	40

Daniel A. Laheru

153

Publications

31.5K

Citations

H-Index

Page 1

	Year	Citations
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, New England Journal of Medicine	2013	6.5K
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies Chetan Bettegowda, Mark Sausen, Rebecca Leary, Science Translational Medicine Dna AnalysisPathologyVarious Cancer TypesNucleic Acid BiomarkersTumor Biology	2014	5K
<i>DPC4</i> Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer Christine A. Iacobuzio–Donahue, Baojin Fu, Shinichi Yachida, Journal of Clinical Oncology	2009	1.1K
Gemcitabine Plus<i>nab</i>-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial Daniel D. Von Hoff, Ramesh K. Ramanathan, Mitesh J. Borad, Journal of Clinical Oncology	2011	1K
Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation Elizabeth M. Jaffee, Ralph H. Hruban, Barbara Biedrzycki, Journal of Clinical Oncology	2001	592
Safety and Survival With GVAX Pancreas Prime and <i>Listeria Monocytogenes</i>–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer Dung T. Le, Andrea Wang‐Gillam, Vincent J. Picozzi, Journal of Clinical Oncology	2015	588
PD-1 blockade in tumors with mismatch repair deficiency. Dung T. Le, Jennifer N. Uram, Hao Wang, Journal of Clinical Oncology Tumor BiologyTumoral PathologyMalignant DiseasePd-1 BlockadeMedicine	2015	553
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer Dung T. Le, Eric R. Lutz, Jennifer N. Uram, Journal of Immunotherapy ImmunologyGm-csf GeneImmune Cell TherapyImmunotherapyCancer Biology	2013	547
Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors Shinichi Yachida, Efsevia Vakiani, Catherine M. White, The American Journal of Surgical Pathology Small Cell NecsPancreatic CancerMedicineSurgical PathologyImmunology	2012	530
Phase 2 multi‐institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma Joseph M. Herman, Daniel T. Chang, Karyn A. Goodman, Cancer	2014	526

Page 1